Skip to content
value.today

Tricida

TCDAUnlisted company
$9 Mlast known market cap, Dec 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
$0 M
Dec-2021 ending year
value.today research
Net income
$-176 M
value.today research
Employees
—

Tricida in brief

Tricida is an unlisted company in the Biotechnology industry, based in South San Francisco, California, USA. It was founded in 2013. In the year to Dec 2021 it had sales of $0 M and a net loss of $176 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Tricida

Tricida is a Pharmaceutical company. It is focused on the development and commercialization of its investigational drug candidate, veverimer(is developed for the complications of chronic kidney disease (CKD) including metabolic acidosis), a non absorbed, orally administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease. The headquarters is in USA.

Tricida timeline

3 events, 2013–2018
  1. 2013
  2. 🏁
    Founded
  3. 2014
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2018
  6. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 29 June 2018; shares registered for exchange trading on 25 June 2018.

Events of Tricida from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Tricida

Acquisitions and changes
Delisted: it ended its SEC registration (Form 15) on 13 June 2023.

Market cap history

$0 M$497 M$994 M$1.5 B$2.0 B202020212022

World rank over time

▼ down 26,271 places since 2020
2020-01-01: #5405#5,40520202021-01-01: #12891#12,89120212022-01-07: #13546#13,54620222022-12-25: #31676#31,6762022

Rank in USA: #1,513 (Jan 2020) · #2,820 (Jan 2021) · #2,938 (Jan 2022) · #5,608 (Dec 2022)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-88000.0%
Liabilities / assets
100.0%
Net debt
$-21M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2016: revenue —, net income $-29M—FY16Fiscal year ending Dec 2017: revenue —, net income $-41M—FY17Fiscal year ending Dec 2018: revenue —, net income $-103M—FY18Fiscal year ending Dec 2019: revenue —, net income $-177M—FY19Fiscal year ending Dec 2020: revenue —, net income $-265M—FY20Fiscal year ending Dec 2021: revenue —, net income $-177M—FY21
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2021——$-153M$-177M—
Dec 2020——$-251M$-265M—
Dec 2019——$-179M$-177M—
Dec 2018——$-104M$-103M—
Dec 2017——$-47M$-41M—
Dec 2016——$-27M$-29M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2021$-140M$0M$-140M$-3.44—
Dec 2020$-231M$2M$-233M$-5.29—
Dec 2019$-130M$1M$-131M$-3.72—
Dec 2018$-95M$1M$-96M$-4.64—
Dec 2017$-40M$1M$-41M$-19.32—
Dec 2016$-23M$0M$-23M$-15.69—

SEC filings

Official filings of Tricida with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
—
Net income
$-176 M

Dec-2021 ending year

Balance sheet

Total assets
$168 M
Total liabilities
$168 M
Total equity
$0 M

Dec-2021 ending year

Insider trading at Tricida#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
35
since
Tricida: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Orbimed Advisors LLCDirector, 10% ownerSellindirect-3.63 M$0.220—0Form 4
filed David P. BonitaDirector, 10% ownerSellindirect-3.63 M$0.220—0Form 4
filed Robert J. AlpernDirectorSell-131,879$0.210—0Form 4
filed David P. BonitaDirector, 10% ownerSellindirect-5.62 M$0.210—3.63 MForm 4
filed Orbimed Advisors LLCDirector, 10% ownerSellindirect-5.62 M$0.210—3.63 MForm 4
filed Orbimed Advisors LLCDirector, 10% ownerSellindirect-1.03 M$0.220—9.25 MForm 4
filed David P. BonitaDirector, 10% ownerSellindirect-1.03 M$0.220—9.25 MForm 4
filed Robert J. AlpernDirectorSell-27,584$0.230—131,879Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Tricida#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 1-for-3.98 reverse split

Bankruptcy filing: (8-K); (8-K); (8-K)

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Tricida scorecard#

Passes 3 of the 11 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 3). Fiscal year 2021.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.44 vs -5.29Diluted EPS -3.44 in fiscal 2021 against -5.29 the year before (report's currency).
    • ✗Net income higher than five years earlier-$177 M-$177 M in fiscal 2021 against -$29 M in 2016.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$177 MNet income -$177 M in fiscal 2021.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2021.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-323.7%-323.7% in fiscal 2021.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities4.9×Current ratio 4.94 at the end of fiscal 2021.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2021.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $21 M at the end of fiscal 2021.
    • ✗Operating income covers interest five times-8.7×Operating income -8.7 times interest in fiscal 2021.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2021.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.5%Diluted shares up 2.5% in fiscal 2021.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Tricida: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Tricida: statements by fiscal year
PeriodTrendFY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development115148133863622
Selling, general and administrative381034618115.4
Operating expenses1532511791044727
Operating income−153−251−179−104−47−27
Interest and finance income0.54.48.73.50.40.2
Interest expense and finance costs18185.73.100
Other non-operating income (expense)0.15.07.73.90.20.1
Income tax00−0.100—
Net income attributable to shareholders−177−265−177−103−41−29
Earnings per share, basic-3.44-5.29-3.72-4.64-19.32-15.69
Earnings per share, diluted-3.44-5.29-3.72-4.64-19.32-15.69
Shares, weighted average (basic)5150————
Shares, weighted average (diluted)515048222.11.8
Balance sheet
Cash and cash equivalents2113819379.85.7
Short-term investments11917228920458—
Other current assets5.04.54.73.31.9—
Current assets14631431324469—
Property, plant and equipment0.81.12.71.21.2—
Right-of-use (leased) assets12149.4———
Total assets16935237224871—
Accounts payable103.55.98.53.9—
Debt due within a year——0———
Current liabilities2934401511—
Long-term debt07758380—
Lease liabilities (non-current)11138.8———
Non-current liabilities————0.3—
Total liabilities1682431085312—
Retained earnings−810−634−369−192−89—
Shareholders' equity0.2109264195−88−48
Total liabilities and equity16935237224871—
Shares outstanding555050422.3—
Cash-flow statement
Share-based compensation2628255.20.90.3
Cash from operating activities−140−231−130−95−40−23
Capital expenditure−0.1−1.6−1.4−0.9−1.0−0.2
Cash from investing activities64140−127−148−38−20
Debt issued———3900
Debt repaid———−0.1−0.0−0.0
Shares issued75—————
Cash from financing activities−412102382718243
Change in cash−117119−19274.1−0.4
Report10-K10-K10-K10-K10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2022. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Tricida#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Bankruptcy or receivership 3 · Delisting notice 3 · Debt called early 2 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 7 · Agreement ended 1 · New debt 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 6

Tricida: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivershipShareholder rights changed8-K
Bankruptcy or receivership8-K
Directors and officers8-K
Acquisition or sale completed8-K
Material agreement8-K
Directors and officers8-K
Delisting notice8-K
Bankruptcy or receivershipDebt called earlyDirectors and officersMaterial agreementBylaws or fiscal year changed8-K
Debt called early8-K
Delisting noticeAgreement ended8-K
Delisting notice8-K
Directors and officers8-K
Results announced8-K
Material agreementNew debt8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officersResults announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jun 13, 2023

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Tricida
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2017$58 MNo. 4$50 to $250 million13equitySEC
Jul 2016$24 MNo. 3$10 to $50 million6equitySEC
Feb 2015$17 MNo. 2$10 to $50 million4equitySEC
Dec 2013$5 MNo. 1$2 to $10 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Tricida#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
93
2020–2020
Latest
93 people
2020-10-25
Tricida: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2020·········93··93
Tricida: latest layoffs
AnnouncedPeopleKindWhereSource
93 peopleRestructuring planSEC 8-K“Under the restructuring plan, the Company is reducing its workforce by 93 employees (approximately 60%).”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Tricida compares in Biotechnology

  • Revenue$0 M · higher than 0% of 647

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Tricida🇺🇸$9 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Dec 25, 2022 (last known)
Annual results:
Dec-2021 ending year
Balance sheet:
Dec-2021 ending year
Profile updated:
Nov 16, 2026

Figures from value.today research, Wikidata.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Tricida? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Tricida's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Tricida? Suggest a correction